GSK's B7-H3-targeted Antibody-Drug Conjugate, GSK'227, Receives Orphan Drug Designation in the EU
October 28, 2025
October 28, 2025
LONDON, England, Oct. 28 -- GSK (formerly GlaxoSmithKline), a biopharmaceutical company, issued the following news release:
* * *
GSK's B7-H3-targeted antibody-drug conjugate, GSK'227, receives Orphan Drug Designation in the EU
* Regulatory designation based on encouraging early clinical data showing potential for GSK'227 in small-cell lung cancer
* Patients with relapsed or refractory extensive stage small-cell lung cancer often . . .
* * *
GSK's B7-H3-targeted antibody-drug conjugate, GSK'227, receives Orphan Drug Designation in the EU
* Regulatory designation based on encouraging early clinical data showing potential for GSK'227 in small-cell lung cancer
* Patients with relapsed or refractory extensive stage small-cell lung cancer often . . .